- Home
- NUVB vs HSII Comparison
NUVB vs HSII Comparison
Compare NUVB & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- HSII
- Stock Information
- Founded
- NUVB 2018
- HSII 1953
- Country
- NUVB United States
- HSII United States
- Employees
- NUVB N/A
- HSII N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- HSII Diversified Commercial Services
- Sector
- NUVB Health Care
- HSII Consumer Discretionary
- Exchange
- NUVB Nasdaq
- HSII Nasdaq
- Market Cap
- NUVB 1.1B
- HSII 1.1B
- IPO Year
- NUVB N/A
- HSII 1999
- Fundamental
- Price
- NUVB $3.28
- HSII $49.99
- Analyst Decision
- NUVB Strong Buy
- HSII Buy
- Analyst Count
- NUVB 6
- HSII 2
- Target Price
- NUVB $8.17
- HSII $51.00
- AVG Volume (30 Days)
- NUVB 6.7M
- HSII 94.6K
- Earning Date
- NUVB 11-05-2025
- HSII 11-03-2025
- Dividend Yield
- NUVB N/A
- HSII 1.20%
- EPS Growth
- NUVB N/A
- HSII N/A
- EPS
- NUVB N/A
- HSII 1.60
- Revenue
- NUVB $14,355,000.00
- HSII $1,155,576,000.00
- Revenue This Year
- NUVB $332.80
- HSII $11.33
- Revenue Next Year
- NUVB $360.12
- HSII $0.90
- P/E Ratio
- NUVB N/A
- HSII $31.21
- Revenue Growth
- NUVB 900.35
- HSII 9.00
- 52 Week Low
- NUVB $1.54
- HSII $36.49
- 52 Week High
- NUVB $4.09
- HSII $52.18
- Technical
- Relative Strength Index (RSI)
- NUVB 58.18
- HSII 54.48
- Support Level
- NUVB $3.20
- HSII $49.05
- Resistance Level
- NUVB $3.41
- HSII $52.16
- Average True Range (ATR)
- NUVB 0.27
- HSII 1.27
- MACD
- NUVB -0.03
- HSII -0.21
- Stochastic Oscillator
- NUVB 33.55
- HSII 30.23
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.